Antiemetic research: Future directions

Supportive Care in Cancer

Volumn 19, Issue SUPPL. 1, 2011, Pages

  Olver, Ian ^a   Molassiotis, Alexander ^b   Aapro, Matti ^c   Herrstedt, Jørn ^d   Grunberg, Steven ^e   Morrow, Garry ^f  

^a CANCER COUNCIL AUSTRALIA   (Australia)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF VERMONT   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Antiemetics; Chemotherapy; Future research; Methodology; Nausea; Vomiting

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; APREPITANT; CAPECITABINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GHRELIN; GRANISETRON; IMATINIB; LEVONANTRADOL; NABILONE; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE; TROPISETRON;

AGITATION; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHEMOTHERAPY INDUCED NAUSEA NAD VOMITING; COST BENEFIT ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG BINDING; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ELECTROACUPUNCTURE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GENETIC RISK; HUMAN; INCREASED APPETITE; INSOMNIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; NAUSEA; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VOMITING;

EID: 79953331929     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-1036-1     Document Type: Article

References (52)

1. Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachman C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088
2. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed Nausea and Vomiting Continue to Reduce Patients'Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment. J Clin Oncol 24:4472-4478 (Pubitemid 46630986)
3. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; on behalf of the Sancuso Study Group (2010) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. doi:10.1007/s00520-010-0990- y
4. Brearley SG, Clements CV, Molassiotis A (2008) A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer 16:1213-1229
5. Burke TA, Wisniewski T, Ernst FR (2010) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer. doi:10.1007/s00520-009-0797-x
6. Celio L, Frustaci S, Denaro A, et al; for the Italian Trials in Medical Oncology Group (2010) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer (in press)
7. Cella D, Eton DT, Fairclough DL, Bonomi P, Hayes AE, Silberman C, Wolf MK, Johnson DH (2002) What is clinically meaningful change on the Functional Assessment Cancer Threrapy - Lung (FACT-L) quesionnaire? Results form Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55:285-295 (Pubitemid 34195525)
8. Darmani NA, Janoyan JJ, Crim J, Ramirez J (2007) Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol 563:187-196 (Pubitemid 46602236)
9. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij (1997) Patient perceptions of the side effects of chemotherapy: the influence of the 5-HT3 antagonists. Br J Cancer 76:1055-1061
10. De Mulder PH, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicentre, randomized, double-blind, crossover study. Ann Intern Med 113:834-840
11. Dranitsaris G, Leung P, Warr D (2001) Implementing evidence-based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9:611-618 (Pubitemid 33063722)
12. Ezzo JM, Richardson MA, Vickers A, Allen C, Dibble SL, Issell BF, Lao L, Pearl M, Ramirez G, Roscoe J, Shen J, Shivnan JC, Streitberger K, Treish I, Zhang G (2006) Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 19(2):2285
13. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242-247
14. Hainsworth JD (1992) The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol 19:48-52
15. Hargreaves R (2002) Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 63:18-24
16. Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112:2080-2087 (Pubitemid 351574085)
17. Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171-1177
18. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109 (Pubitemid 27020563)
19. Hickok JT, Roscoe JA, Morrow GR (2001) The role of patients' expectations in the development of anticipatory nausea related to chemotherapy for cancer. J Pain Symptom Manage 22:843-850 (Pubitemid 32884377)
20. Jakobsen JN, Herrstedt J (2009) Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients. Crit Rev Oncol Hematol 71:214-221
21. Jiang J, Bunda JL, Doss GA, Chicchi GG, Kurtz MM, Tsao KL, Tong X, Zheng S, Upthagrove A, Samuel K, Tschirret-Guth R, Kumar S, Wheeldon A, Carlson EJ, Hargreaves R, Burns D, Hamill T, Ryan C, Krause SM, Eng W, DeVita RJ, Mills SG (2009) Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem 52:3039-3046
22. Jordan K, Sippel C, Schmoll H-J (2007) Guidelines for Antiemetic Treatment of The Oncologist 12: 1143-1150
23. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmöller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytrptamine type 3 receptor antagonists according to cytochrome P-450 2wD6 genotypes. J Clin Oncol 20:2765-2767
24. Keire DA, Bowers CW, Solomon TE, Reeve JR Jr (2002) Structure and receptor binding of PYY analogues. Peptides 23:305-321 (Pubitemid 34127968)
25. Lajolo PP, de Camargo B, del Giglio A (2009) Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. Am J Clin Oncol 32:23-26
26. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98:645-655
27. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage 34:148-159 (Pubitemid 47096779)
28. Molassiotis A, Helin AM, Dabbour R, Hummerston S (2007) The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. Complement Ther Med 15:3-12 (Pubitemid 46359918)
29. Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201-208
30. Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA (2008) Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care 17:444-453
31. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10:139-145 (Pubitemid 36056310)
32. Morrow GR (1985) The effect of susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 55:2766-2770
33. Navari RM, Einhorn LH, Snr LPJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285-1291 (Pubitemid 47583449)
34. Okumura M, Arakawa R, Ito H, Seki C, Takahashi H, Takano H, Haneda E, Nakao R, Suzuki H, Suzuki K, Okubo Y (2008) Suhara T (2008) Quantitative analysis of NK1 receptor in the human brain using PET with 18 F-FE-SPA-RQ. J Nucl Med 49:1749-175
35. Olver IN, Taylor AE, Whitford H (2005) Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences. Psycho-oncol 14:25-33 (Pubitemid 40124671)
36. Osoba D (2000) Health-related quality-of-life assessment in clinical trials of supportive care in oncology. Support Care Cancer 8:84-88
37. Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P (2010) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer. doi:10.1007/s00520-010-0982-y
38. Pollera CF, Gimelli D (1989) Prognostic factors influencing cisplatin induced emesis. Definition and validation of a predictive logistic model. Cancer 64:1117-1122
39. Roscoe JA, Bushunow P, Jean-Pierre P, Heckler CE, Purnell JQ, Peppone LJ, Chen Y, Ling MN, Morrow GR (2009) Acupressure bands are effective in reducing radiation therapy-related nausea. J Pain Symptom Manage 38:381-389
40. Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L, Hoelzer K, Jacobs A (2010) Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18:869-876
41. Rudd JA, Cheng CH, Naylor RJ, Ngan MP, Wai MK (1999) Modulation of emesis by fentanyl and opioid receptor antagonists in Suncus murinus (house musk shrew). Eur J Pharmacol 374:77-84 (Pubitemid 29296728)
42. Soukoup M (1996) Management of cyclophosphamide-induced emesis over repeated courses. Oncology 53:39-45
43. Sullivan JR, Leyden MJ, Bell R (1983) Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. New Engl J Med 309:796 (Pubitemid 13004295)
44. Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131
45. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16-21 (Pubitemid 32681999)
46. Tremblay PB, Kaiser R, Sezer O, Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I, Brockmoller J (2003) Variations in the 5hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer. J Clin Oncol 21:2147-2155 (Pubitemid 46606363)
47. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol selectively acts on CB I receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285:566-57
48. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011-1015
49. Warel MA, Daeninck P, Maida V (2008) A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 4:99-107 (Pubitemid 351460935)
50. Warr DG, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. doi:10.1007/s00520-010-0899-5
51. Yakabi K, Sadakane C, Noguchi M, Ohno S, Ro S, Chinen K, Aoyama T, Sakurada T, Takabayashi H, Hattori T (2010) Reduced ghrelin secretion in the hypothalamus of rats due to cisplatininduced anorexia. Endocrinology 151:3773-3782
52. Yeh YC, McDonnell A, Klinger EV, Fowler B, Matta L, Voit D, Reddy P (2010) Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. doi:10.1177/1078155210366491